Ann: Appendix 3B and Appendix 3Y, page-4

What I'm wondering is why they structured the options in this way? If she signs a commercial deal (lets pray for the next 3 months), and the share price goes above 25 cents, why not have the second tranche of options at 35 cents then the last lot at 45 cents? Plus I would have reversed the order of options. (1 million, 1 million and then 5 million if she delivers a commercial deal with the share price at 45 cents - Now that's an incentive). To me the current set up is a strange methodology, to have the second and third tranche at a lower price doesn't provide an incentive, it merely provides a reward for achieving the first goal. Are they thinking the share price will spike then drop?
Coming away from the AGM, I am confident a deal is being put together (lets all hope so), but i think it will be Hep B whilst the toxicology profile is worked up over a 6, 9 and 12 month periods. Therefore I think we will see multiple announcements over 2020.